(-)-Blebbistatin: Selective Non-Muscle Myosin II Inhibitor for Cytoskeletal Dynamics

Executive Summary: (-)-Blebbistatin (B1387) is a highly selective, cell-permeable inhibitor of non-muscle myosin II (NM II) that acts by stabilizing the myosin-ADP-phosphate complex and suppressing actomyosin contractility (APExBIO). It demonstrates an IC₅₀ of 0.5–5.0 μM for NM II, exhibits minimal activity against myosin isoforms I, V, and X, and shows greatly reduced potency for smooth muscle myosin II (IC₅₀ ~80 μM) (gdc-0349.com). Its DMSO solubility (≥14.62 mg/mL) enables flexible experimental integration, but it is insoluble in water and ethanol. The compound is widely used to investigate cytoskeletal dynamics, cardiac muscle contractility, and developmental biology, yet care must be taken to avoid off-target effects and ensure solution stability (cy7-carboxylic-acid.com).

Biological Rationale

Non-muscle myosin II (NM II) is a critical actin-dependent motor protein mediating cell adhesion, migration, and morphogenesis. NM II-driven contractility underlies key biological processes including cytokinesis, cell motility, tissue morphogenesis, and wound healing (Wu et al., 2025). Actin-myosin interactions also shape cardiac tissue contractility and play a role in disease mechanisms such as MYH9-related disorders and cancer progression. Selective chemical inhibition enables the dissection of NM II function without disrupting other myosin isoforms or cytoskeletal elements. (-)-Blebbistatin provides researchers with a reversible, highly selective means to probe these pathways in living cells, tissues, and organisms (APExBIO).

Mechanism of Action of (-)-Blebbistatin

(-)-Blebbistatin binds to the myosin-ADP-phosphate complex and stabilizes it in a conformation that prevents phosphate release. This action slows the Mg-ATPase cycle and suppresses actomyosin contractile function. Inhibition is reversible and highly selective for NM II, with an IC₅₀ between 0.5 and 5.0 μM under standard in vitro conditions (20–25°C, neutral pH, physiological buffer) (APExBIO). It exhibits minimal inhibitory activity on myosin I, V, and X, and a markedly weaker effect on smooth muscle myosin II (IC₅₀ ~80 μM). (-)-Blebbistatin does not covalently modify myosin and is considered a reversible inhibitor, allowing for temporal control in experimental setups. The compound’s selectivity is rooted in its affinity for the structural conformation unique to NM II during its ATPase cycle (pamidronatedisodium.com).

Evidence & Benchmarks

• (-)-Blebbistatin inhibits non-muscle myosin II Mg-ATPase activity with an IC₅₀ of 0.5–5.0 μM in vitro (APExBIO, product page).
• It is highly selective for NM II, with minimal inhibition of myosin I, V, and X at tested concentrations (cytochalasin-d.com).
• For smooth muscle myosin II, (-)-Blebbistatin exhibits an IC₅₀ of ~80 μM, indicating poor potency and strong isoform selectivity (pamidronatedisodium.com).
• Stock solutions are stable in DMSO at -20°C for several months, but solutions should be protected from light and used promptly to avoid degradation (cy7-carboxylic-acid.com).
• In zebrafish embryos, (-)-Blebbistatin induces dose-dependent cardia bifida, demonstrating in vivo efficacy and developmental relevance (gdc-0349.com).
• Cardiac muscle studies confirm that (-)-Blebbistatin inhibits actin-myosin interaction and suppresses contractility without affecting HCN4-mediated pacemaker currents (Wu et al., 2025).

This article expands on '(-)-Blebbistatin: Precise Non-Muscle Myosin II Inhibition…' by providing updated benchmarks for off-target selectivity and long-term storage, as well as new insights into cardiac-specific applications.

Applications, Limits & Misconceptions

(-)-Blebbistatin is widely used in studies of cell adhesion, migration, cytokinesis, and tissue morphogenesis. It is a key reagent for modeling cardiac muscle contractility, investigating MYH9-related disease mechanisms, and exploring tumor mechanics in cancer research. The compound is also employed in developmental biology, including zebrafish and murine embryology, to dissect actomyosin contractility pathways. Recent translational research leverages (-)-Blebbistatin to study caspase signaling and mechanotransduction in disease models (cytochrome-c-fragment-93-108.com), extending beyond foundational cytoskeletal research. This article clarifies the reversible nature of inhibition and offers specific parameter guidance, updating the best practices outlined in '(-)-Blebbistatin: A Selective Non-Muscle Myosin II Inhibi…'.

Common Pitfalls or Misconceptions

• Non-specific effects at high concentrations: Use above 20 μM may induce off-target cytotoxicity or phototoxicity, particularly under prolonged light exposure.
• Ineffectiveness against smooth muscle myosin II: The IC₅₀ of ~80 μM is too high for practical experimental inhibition without toxicity.
• Solubility limitations: (-)-Blebbistatin is insoluble in water and ethanol; DMSO is required for stock solutions.
• Stability concerns: Light and repeated freeze-thaw cycles degrade the compound; use freshly thawed, protected solutions.
• Not a pan-myosin inhibitor: Minimal effect on myosin isoforms I, V, and X means it cannot be used for broad-spectrum myosin inhibition.

Workflow Integration & Parameters

To prepare (-)-Blebbistatin for experimental use, dissolve the compound in DMSO at ≥14.62 mg/mL, applying gentle warming or brief ultrasonic treatment to enhance solubility. Store aliquots at -20°C, protected from light. Working concentrations typically range from 1 to 20 μM, with 0.1–0.5% DMSO in the final medium. Avoid repeated freeze-thaw cycles and use solutions promptly after thawing. For in vivo models, titrate dose based on developmental stage and desired contractility suppression. The B1387 kit from APExBIO includes validated protocols for optimal use (APExBIO product page).

For further technical guidance, see '(-)-Blebbistatin: A Gold Standard Non-Muscle Myosin II In…', which details live-cell and tissue model protocols. This article adds explicit solvent recommendations and troubleshooting for compound stability.

Conclusion & Outlook

(-)-Blebbistatin remains a gold-standard reagent for selective, reversible inhibition of non-muscle myosin II in cellular and developmental studies. Its robust selectivity profile, DMSO solubility, and well-validated workflows enable precise dissection of actin-myosin interactions in a variety of systems. Ongoing research continues to expand its utility in disease modeling, mechanotransduction studies, and translational applications. Practitioners should follow storage and handling best practices to maximize experimental reproducibility and minimize artifacts. For comprehensive data and ordering, refer to the (-)-Blebbistatin product page at APExBIO.